NEW YORK — FDA-approved generic and biosimilar medicines are key to America’s health care, filling nine out of ten prescriptions dispensed in the United States. Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM), recently partnered with YourUpdate TV on a nationwide media tour to discuss why reliable, affordable, high-quality prescription medication
WASHINGTON — Today, the Association for Accessible Medicines (AAM), the trade association of generic and biosimilar manufacturers, released the topline findings from its forthcoming 2021 Generic Drug and Biosimilars Savings in the U.S. report highlighting the value of generic and biosimilar drugs. According to the analysis, the U.S. health care system saved $338 billion in
WASHINGTON — The Association for Accessible Medicines (AAM) today released a white paper, “New Generics Are Less Available in Medicare Than Commercial Plans.” New generic entrants benefit patients and the health care system by introducing competition for high-priced drugs. However, new evidence confirms that the Medicare Part D Program continues to underperform compared to commercial
WASHINGTON – Steven Selde has joined the Association for Accessible Medicines (AAM) as director of the Biosimilars Council. This division of AAM educates the public and patients about the safety and effectiveness of biosimilars, focusing on access, the regulatory environment, reimbursement and legal affairs. Member organizations include manufacturers and stakeholders working to develop biosimilar products
WASHINGTON – Today the Association for Accessible Medicines (AAM) and its Biosimilars Council shared their policy priorities for the Biden administration and 117th Congress, highlighting solutions to maintain the sustainability of generic and biosimilar competition. In parallel, AAM launched a new advocacy campaign, “Secure Our Meds,” which includes a series of reports emphasizing the importance and
